Comparative efficacy of sodium‐glucose co‐transporter‐2 inhibitors, glucagon‐like peptide‐1 receptor agonists and non‐steroidal mineralocorticoid receptor antagonists in chronic kidney disease and type 2 diabetes: A systematic review and network meta‐analysis
Diabetes, Obesity and Metabolism · 2023
DOI: 10.1111/dom.15009 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Diabetes, Obesity and Metabolism, 2023. Verfasst von Bao-Ngoc Nguyen und 4 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Memorial University of Newfoundland, St. John's, Newfoundland and Labrador, Canada. Hauptthemen laut MEDLINE: Cardiovascular Diseases, Diabetes Mellitus, Type 2, Renal Insufficiency, Chronic, Sodium-Glucose Transporter 2 Inhibitors. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 56 Literaturangaben.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Aim
To compare the relative efficacy of sodium‐glucose co‐transporter 2 inhibitors (SGLT‐2is), glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) and non‐steroidal mineralocorticoid receptor antagonists (nsMRAs) in improving the cardiovascular and renal outcomes in patients with type 2 diabetes (T2D) and chronic kidney disease (CKD). Materials and Methods We searched PubMed, Embase and Cochrane Library from inception through 25 November 2022. We selected randomized controlled trials that studied patients with CKD and T2D with a follow‐up of at least 24 weeks and compared SGLT‐2is, GLP‐1RAs and nsMRAs with each other and with placebo. Primary outcomes were major adverse cardiovascular events (MACE) and composite renal outcomes (CRO). Secondary outcomes were cardiovascular death, all‐cause death, stroke, myocardial infarction and heart failure hospitalization (HFH). A frequentist approach was used to pool risk ratios (RRs) with 95% confidence intervals (CIs).
Results
Twenty‐nine studies with 50 938 participants for MACE and 49 965 participants for CRO were included. SGLT‐2is did not significantly reduce MACE but were associated with significantly lower risks of CRO compared with GLP‐1RAs (RR, 0.77; 95% CI, 0.64‐0.91; P = .003) and nsMRAs (RR, 0.78; 95% CI, 0.68‐0.90; P = .001). Compared with GLP‐1RAs and nsMRAs, SGLT‐2is significantly reduced risks of HFH by 31% (RR, 0.69; 95% CI, 0.55‐0.88; P = .002) and 22% (RR, 0.78; 95% CI, 0.63‐0.95; P = .016), respectively, but did not significantly reduce other secondary outcomes. There were no significant differences between GLP‐1RAs and nsMRAs in lowering all outcomes.
Conclusions
SGLT‐2is were associated with better cardiorenal protection than GLP‐1RAs and nsMRAs in patients with CKD and T2D.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Pharmacy, Memorial University of Newfoundland, St. John's, Newfoundland and Labrador, Canada.
- Department of Pharmacy, General Hospital of Post and Telecommunication, Ho Chi Minh City, Vietnam.
- College of Pharmacy, University of Manitoba, Winnipeg, Manitoba, Canada.
ORCID-Profile: Bao-Ngoc Nguyen
Zitieren
APA
Nguyen, B. N., Nguyen, L., Mital, S., Bugden, S., & Nguyen, H. V. (2023). Comparative efficacy of sodium‐glucose co‐transporter‐2 inhibitors, glucagon‐like peptide‐1 receptor agonists and non‐steroidal mineralocorticoid receptor antagonists in chronic kidney disease and type 2 diabetes: A systematic review and network meta‐analysis. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.15009
Vancouver
Nguyen BN, Nguyen L, Mital S, Bugden S, Nguyen HV. Comparative efficacy of sodium‐glucose co‐transporter‐2 inhibitors, glucagon‐like peptide‐1 receptor agonists and non‐steroidal mineralocorticoid receptor antagonists in chronic kidney disease and type 2 diabetes: A systematic review and network meta‐analysis. Diabetes, Obesity and Metabolism. 2023. doi:10.1111/dom.15009
BibTeX
@article{Nguyen2023,
author = {Nguyen, Bao-Ngoc and Nguyen, Le and Mital, Shweta and Bugden, Shawn and Nguyen, Hai V},
title = {Comparative efficacy of sodium‐glucose co‐transporter‐2 inhibitors, glucagon‐like peptide‐1 receptor agonists and non‐steroidal mineralocorticoid receptor antagonists in chronic kidney disease and type 2 diabetes: A systematic review and network meta‐analysis},
journal = {Diabetes, Obesity and Metabolism},
year = {2023},
doi = {10.1111/dom.15009}
}
EUVIMED